Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software to the pharmaceutical industry, announces the appointment of Robert D. Clark, Ph.D., to the position of Director, Life Sciences.
Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “We’re excited that Bob will join Simulations Plus in January to lead our Life Sciences team. After Dr. John Crison’s resignation in late October we began our search. Bob had done some work for us as a consultant earlier, through which we gained a greater appreciation for his expertise and his reputation as an outstanding scientist. Bob comes to us with over 25 years of experience in discovery chemistry as well as managing the development of software tools for pharmaceutical and chemical research. He held the position of vice president of science and research at a well-known formerly public company that provides software used in early discovery chemistry. Bob holds a Ph.D. from Cornell University in biochemistry, statistics and biometry, where he was the recipient of a National Science Foundation graduate fellowship. His experience includes a broad spectrum of pharmaceutical and agricultural chemical research and development. He is already a knowledgeable user of Simulations Plus’ state-of-the-art ClassPharmer™ and ADMET Predictor™ software programs, and has hands-on knowledge of other key pharmaceutical research software tools. We believe that Bob’s combination of pharmaceutical science knowledge and experience, his experience in leading software development teams, and his experience as an executive officer in a public company will serve Simulations Plus well as we look to accelerate our continued growth in the coming months and years. Bob is well-known in the industry and we expect that, in addition to leading our software development teams, he’ll also be making significant contributions to our marketing and sales efforts through attendance and networking at scientific meetings around the world.”
Dr. Clark added: “The scientists at Simulations Plus have built a remarkably impressive set of drug discovery and development tools, and collaborating with them has been a pleasure. I look forward to joining the team full-time.”